Partial
Mostly Aligned
Patient Risk:
Info
Summary
Some mechanistic statements align with the provided labeling excerpt (MOA via dihydrofolate reductase and effects on DNA synthesis/replication), but several interaction-effect claims (e.g., reduced tolerability, efficacy cancellation vs adverse-effect predominance, and dependence on regimens) are not supported by the provided label sections (only MOA excerpt and partial dosing modifications/warnings headings).
Category Scores
Accurate Statements
Methotrexate (MTX) is an antifolate.
Label section provided under 12.1: Methotrexate inhibits dihydrofolic acid reductase, interfering with synthesis of purine nucleotides and thymidylate via folate-dependent one-carbon carriers.
Methotrexate (MTX) can change the effectiveness and toxicity of several medicines because it affects folate pathways.
Label 12.1 Mechanism: Inhibits dihydrofolic acid reductase, reduces folate required for one-carbon group carriers used in purine and thymidylate synthesis; interferes with DNA synthesis/repair/replication in sensitive tissues.
Unsupported Statements
Drugs that depend on folate pathways can have their activity altered by methotrexate through overlap at the same pathway or through folate depletion effects.
Provided label excerpt describes methotrexate MOA and downstream effects, but does not describe folate depletion-driven interactions or pathway overlap mechanisms with other drugs.
Methotrexate interactions with other antifolates (such as pemetrexed) are an example of folate-pathway drug interaction.
No drug-drug interaction examples or mention of pemetrexed are present in the provided label excerpts.
Methotrexate interactions can result in reduced tolerability.
The provided excerpts include dosage modifications for various toxicities in general (e.g., myelosuppression, hepatotoxicity, pulmonary toxicity), but do not state that drug interactions cause reduced tolerability.
Methotrexate interactions can, in some regimens, change effectiveness or dose feasibility.
The provided excerpts do not describe interaction-specific effects on efficacy or dose feasibility.
In many real-world interactions, methotrexate more reliably increases the risk of adverse effects (and forces dose changes) than it directly cancels efficacy.
No comparative/relative-frequency statements or “real-world” generalizations are supported by the provided label excerpts.
Drug choice and schedule for methotrexate interactions depend on the specific MTX dose, kidney function, and whether the other drug is also an antimetabolite or antifolate.
The provided excerpts include a limited list of dosing modifications for adverse reactions but do not specify interaction-based regimen selection criteria, nor do they describe a dependence on kidney function or other-drug class for interaction management.
Contradictions
Important Omissions
No evaluation of contraindications, boxed warnings, or specific interaction warnings (e.g., detailed interaction section content) was possible because no label text for contraindications/boxed warnings/drug interactions was provided beyond the empty 7 DRUG INTERACTIONS section header and limited dosing-modification lists.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
Unsupported interaction-effect claims (especially regimen-dependence, interaction-driven tolerability, and efficacy changes) could mislead, but no explicit patient-management instructions were provided in the claims beyond general statements; provided label excerpts do not corroborate these interaction assertions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several drug-interaction and consequence claims are not supported by the provided label excerpts.
Suggested Improvement
Limit statements to the provided MOA (inhibition of dihydrofolate reductase, effects on DNA synthesis/replication) and remove or qualify interaction-specific claims unless the corresponding FDA label drug-interaction text is provided.